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Abstract
 
Integrin-associated protein (CD47) is a broadly expressed protein that costimulates T cells, fa-
cilitates leukocyte migration, and inhibits macrophage scavenger function. To determine the
role of CD47 in regulating alloresponses, CD47
 
 
 
/
 
 
 
 or CD47
 
 
 
/
 
 
 
 T cells were infused into irra-
diated or nonconditioned major histocompatibility complex disparate recipients. Graft-versus-
host disease lethality was markedly reduced with CD47
 
 
 
/
 
 
 
 T cells. Donor CD47
 
 
 
/
 
 
 
 T cells
failed to engraft in immunodeficient allogeneic recipients. CD47
 
 
 
/
 
 
 
 marrow was unable to re-
constitute heavily irradiated allogeneic or congenic immune–deficient CD47
 
 
 
/
 
 
 
 recipients.
These data suggested that CD47
 
 
 
/
 
 
 
 T cells and marrow cells were cleared by the innate im-
mune system. To address this hypothesis, dye-labeled CD47
 
 
 
/
 
 
 
 and CD47
 
 
 
/
 
 
 
 lymphocytes or
marrow cells were infused in vivo and clearance was followed. Dye-labeled CD47
 
 
 
/
 
 
 
 cells
were engulfed by splenic dendritic cells and macrophages resulting in the clearance of virtually
all CD47
 
 
 
/
 
 
 
 lymphohematopoietic cells within 1 day after infusion. Host phagocyte-depleted
CD47
 
 
 
/
 
 
 
 recipients partially accepted allogeneic CD47
 
 
 
/
 
 
 
 T cells. Thus, dendritic cells and
macrophages clear lymphohematopoietic cells that have downregulated CD47 density. CD47
expression may be a critical indicator for determining whether lymphohematopoietic cells will
survive or be cleared.
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Introduction
 
Integrin-associated protein (CD47) is a broadly distributed
glycoprotein expressed on all hematopoietic cells (1).
CD47 regulates leukocyte activation, chemotaxis, and mi-
gration (2–4). CD47 ligation can costimulate activated T
cells (3–6). Conversely, CD47 ligation can function as an
immune inhibitory signal which limits T cell responses (6,
7). Although CD47 ligation has been shown to deliver T
cell costimulatory signals in in vitro assays, there are no re-
ports of the potential role of CD47 costimulation in vivo.
The counterreceptor for CD47 is the signal regulatory pro-
 
tein (SIRP)
 
 
 
, expressed on neutrophils and monocyte-
derived cells including dendritic cells (DCs; references 8 and
9). The binding of SIRP
 
 
 
 to CD47 on T cells is associated
with T cell activation and induction of antigen-specific
CTL responses by DCs (9). Studies in CD47
 
 
 
/
 
 
 
 recipients
infused with nonopsonized or opsonized RBCs obtained
from CD47
 
 
 
/
 
 
 
 or CD47
 
 
 
/
 
 
 
 (10) donors showed that RBC
CD47 must deliver an inhibitory signal via macrophage
SIRP
 
  
 
to prevent clearance and phagocytosis by splenic
macrophages (8, 11). The effects of CD47 expression on
the clearance of other cell types has not been reported.
To determine whether CD47 ligation would facilitate T
cell activation and expansion in vivo, we used an adoptive
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transfer system in which donor T cells expand and cause
target tissue injury known as GVHD in allogeneic recipi-
ents (12). Allogeneic CD47
 
 
 
/
 
 
 
 T cells had a markedly re-
duced capacity to cause GVHD and virtually no CD47
 
 
 
/
 
 
 
T cells were found in lymphoid tissues of CD47
 
 
 
/
 
 
 
 recipi-
ents. Donor CD47
 
 
 
/
 
 
 
 bone marrow (BM) was unable to
rescue irradiated congenic immunodeficient CD47
 
 
 
/
 
 
 
 re-
cipients suggesting that the innate immune system might
be eliminating CD47
 
 
 
/
 
 
 
 cells. Splenic macrophages,
CD11b
 
 
 
, and especially CD11b
 
 
 
 DCs engulfed dye-labeled
CD47
 
 
 
/
 
 
 
 LN cells and CD47
 
 
 
/
 
 
 
 BM cells clearing these
cells within 24 h after infusion in marked contrast to
CD47
 
 
 
/
 
 
 
 cells. The elimination of splenic macrophages
partially restored the capacity of donor CD47
 
 
 
/
 
 
 
 T cells to
engraft in allogeneic recipients, indicating that donor
CD47
 
 
 
/
 
 
 
 T cells can expand in vivo. Thus, host DCs (and
macrophages) can receive negative signals delivered via
CD47 antigen expressed on donor BM cells or donor T
cells. The downregulation of CD47 antigen expression on
lymphohematopoietic cells during disease states may signal
these cells for clearance by host DCs and macrophages.
 
Materials and Methods
 
Mice.
 
C57BL/6 severe combined immune deficient (B6
SCID), B6.129S7 recombination activating gene (Rag)1
 
tm1Mom
 
recombinase 1–deficient (B6-Rag1
 
 
 
/
 
 
 
), C.H2
 
bm1
 
 (bm1),
C.H2
 
bm12
 
 (bm12), and B6.PL-Thy1
 
a
 
/Cy (termed B6-Thy1.1
congenic) mice were purchased from The Jackson Laboratory.
C57BL/6 (termed B6:H2
 
b
 
), B6-CD45.1 congenic, Balb/c SCID
(H2
 
d
 
), and Balb/c wild-type (CD47
 
 
 
/
 
 
 
) mice were purchased
from the National Institutes of Health. B6-CD47 deletional mu-
tant (B6-CD47
 
 
 
/
 
 
 
) and Balb/c CD47
 
 
 
/
 
 
 
 mice were generated
and backcrossed 
 
 
 
10 generations (8, 10).
 
GVHD Generation and Quantification of T Cell Expansion In
Vivo.
 
To determine the effects of CD47 expression on the sepa-
rate contribution of CD4
 
 
 
 or CD8
 
 
 
 T cells to the GVHD re-
sponse, bm12 or bm1 recipients were irradiated with 6.0 Gray
(
 
137
 
Cesium) total body irradiation (TBI) and given CD4
 
 
 
 T cells
(0.03–0.3
 
   
 
10
 
6
 
 cells per recipient) or CD8
 
 
 
 T cells (0.6
 
   
 
10
 
6
 
cells per recipient) from CD47
 
 
 
/
 
 
 
 or CD47
 
 
 
/
 
 
 
 donors (10). He-
matocrit (Hct) values were obtained to assess the degree of
GVHD manifested by BM destruction (13). Survival and weight
curves were monitored (13). To determine the effects of CD47
expression on GVHD mediated by T cells administered under
noninflammatory conditions, nonconditioned Balb/c SCID mice
were depleted of NK cells by anti-asialo–GM1 antisera and given
B6-CD47
 
 
 
/
 
 
 
 or CD47
 
 
 
/
 
 
 
 T cells (0.5 or 2
 
   
 
10
 
6
 
 cells per recip-
ient). To quantify the number of donor T cells present in the
spleen of allogeneic recipients, splenocytes from Balb/c SCID re-
cipients of B6-CD47
 
 
 
/
 
 
 
 or CD47
 
 
 
/
 
 
 
 T cells were analyzed on
days 6–7 after transfer. Cohorts were treated intravenously with
0.2 ml of liposomes loaded with dichloromethylene diphospho-
nate (liposomal DMDP; clodronate) on days 2 and 1 before allo-
geneic T cell transfer to deplete splenic phagocytes (8, 14). As an
additional indicator of donor T cell expansion, cannulae were in-
serted in the thoracic duct of other cohorts of recipients at the
time of peak proliferation (day 6) after BM transplantation
(BMT) and lymphocytes were collected over 18 h (13).
 
MLR Response.
 
B6-CD47
 
 
 
/
 
 
 
 or CD47
 
 
 
/
 
 
 
 T cells were
mixed with irradiated (30 Gray) T cell depleted Balb/c spleno-
 
cyte stimulators, plated in replicates of six into 96-well round-
bottomed plates containing 10
 
5
 
 responders and 10
 
5
 
 irradiated
stimulators, and incubated for 2–8 d (13). Microtiter wells were
pulsed with tritiated thymidine (1 
 
 
 
Ci) for 18 h before harvest-
ing and counted in the absence of scintillation fluid on a 
 
 
 
-plate
reader.
 
Long-Term Engraftment Studies.
 
To determine whether
CD47
 
 
 
/
 
 
 
 recipients could reject donor BM grafts, B6-CD47
 
 
 
/
 
 
 
or B6-CD47
 
 
 
/
 
 
 
 recipients were irradiated (5.5 Gray TBI) and
infused with Balb/c BM cells (10
 
7
 
). To determine whether
CD47
 
 
 
/
 
 
 
 or CD47
 
 
 
/
 
 
 
 BM would engraft and provide long-term
hematopoietic reconstitution, B6 recipients were irradiated (5.5–
6.5 Gray TBI) on day 1 and were reconstituted with Balb/c
CD47
 
 
 
/
 
 
 
 or CD47
 
 
 
/
 
 
 
 T cell depleted BM (107 cells) on day 0
(15). In other studies, B6-Thy1.1 recipients were irradiated (9.0
Gray TBI) and reconstituted with B6-CD45.2 CD47 /  and B6-
CD45.1 CD47 /  BM cells (5   106 each). A cohort was sple-
nectomized 10 d pre-BMT. For chimerism assessment, peripheral
blood mononuclear cells were stained with anti-H2b–PE and
anti-H2d–FITC (BD PharMingen) and analyzed using a FACS-
calibur™ (Becton Dickinson). To preclude a host antidonor T
cell response against donor CD47 /  BM cells, CD47 /  B6-
Rag1 / , or B6-CD47 /  recipients were irradiated (9.5 Gray
TBI) on day 0 and given 5   106 congenic B6-CD47 /  or
CD47 /  BM cells.
Short-Term In Vivo BM Proliferation Assay. To determine
the effect of CD47 expression on the short-term reconstitut-
ing capacity of CD47 /  BM, B6 recipients were irradiated
(9.5 Gray TBI) to eliminate host hematopoiesis and given 3  
106 CD47 /  or CD47 /  BM cells on day 0 (16). To pre-
clude NK cell–mediated graft rejection, cohorts were injected
with anti-NK1.1 (PK136) mAb (200  g) on day 2 to deplete
NK cells. Anti-NK1.1 mAb (100  g) results in depletion by
day 1 and lasts for  14 d. On day 5, 3  Ci of [125I]deoxyuri-
dine and 10 11 molar fluorodeoxyuridine (Amersham Pharma-
cia Biotech) was given. Spleens were harvested on day 6,
rinsed, and incorporated radioactivity determined using a  
counter.
Kinetic Assessment of CD47 /  Lymphohematopoietic Cell Clear-
ance in the Spleen of CD47 /  Recipients. Single cell suspen-
sions of LN cells were prepared from B6-CD47 /  and CD47 / 
mice and labeled with carboxyfluorescein diacetate succinimidyl
ester (CFSE; Molecular Probes) according to the manufacturer’s
protocol. Cells were injected intravenously into unirradiated B6
recipients. Single cell splenocyte suspensions were prepared us-
ing 10 mM EDTA. Cells were incubated on ice with cychrome-
labeled anti-B220, cychrome-labeled anti-CD3, PE-labeled
anti-CD11c, and either allophycocyanin-labeled anti-CD11b or
biotin-labeled anti-F4/80 followed by allophycocyanin-labeled
streptavidin. Data were analyzed on a FACScan™ flow cytome-
ter (Becton Dickinson). A portion of the spleens was frozen in
precooled isopentane, sectioned (10  ), dehydrated in acetone,
rehydrated in PBS, and sequentially incubated with anti-FcR
mAb (2.4G2), avidin/biotin solutions (Vector Laboratories), bi-
otin-labeled anti-CD11c mAb (N418), streptavidin-labeled
horseradish peroxidase (NEN Life Science Products), and Cy5-
labeled tyramide (NEN Life Science Products). Confocal mi-
croscopy and image analysis were performed as described previ-
ously (17).
Statistical Analyses. Group comparisons of continuous data
were made by Student’s t test. Survival data were analyzed by life-
table methods using the Mantel-Peto-Cox summary of chi-
squared. P values   0.05 were considered significant.543 Blazar et al. Brief Definitive Report
Results
CD47 /  T Cells Have a Reduced Capacity to Mediate
GVH-induced Lethality and Fail to Expand In Vivo. To de-
termine whether the CD47 expression on donor T cells
was required for optimal alloresponses in vivo, noncondi-
tioned NK-depleted Balb/c SCID mice were given 0.5 or
2.0     106 purified LN T cells from B6-CD47 /  or
CD47 /  donors (Fig. 1 a). All recipients of CD47 /  T
cells survived long-term, while recipients of CD47 /  T
cells died by 3 wk after transfer.
To assess the potential effects of irradiation in supporting
GVHD lethality and to determine whether differences ex-
isted in the effects of CD47 expression on CD8  versus
CD4  T cell–mediated GVHD lethality, bm1 or bm12 re-
cipients were sublethally irradiated (6 Gray TBI) and given
purified CD8  or CD4  T cells, respectively, from B6-
CD47 /  or CD47 /  donors. CD47 /  CD8  T cells
were rapidly lethal (Fig. 1 b). In contrast, 75% of recipients
of CD47 /  CD8  T cells survived long-term. Day 14
mean Hct values were higher in recipients of CD47 / 
versus CD47 /  T cells (25 vs. 9%, respectively; P   
0.066), reflective of less GVHD-induced tissue destruction
from CD47 /  T cells. Recipients of CD4  T cells from
CD47 /  donors had 25% survival versus 100% survival in
recipients of CD47 /  cells (Fig. 1 c). Day 14 mean Hct
values were significantly higher in recipients of CD47 / 
versus CD47 /  T cells (40 vs. 16%, respectively). Titra-
tion studies revealed a  10-fold reduction in GVH lethal-
ity by CD47 /  versus CD47 /  T cells. Thus, GVHD le-
thality mediated by either CD4  or CD8  CD47 /  T
cells was markedly reduced even in the setting of irradia-
tion-induced tissue injury.
To investigate the mechanism(s) responsible for impaired
GVHD lethality observed with CD47 /  T cells, MLR re-
sponses were analyzed. As compared with CD47 /  T
cells, B6-CD47 /  T cells generated a comparable peak
proliferative response to Balb/c stimulator cells (mean  
SD 6,409   968 vs. 7,709   1,309 cpm [day 3]; 5,175  
827 vs. 5,124   512 cpm [day 4]; P values   0.1]. These
data indicate that CD47 expression was not critical for in
vitro alloproliferation.
It is possible that reduced GVHD by CD47 /  T cells
was due to a defect in the response of CD47 /  T cells to
alloantigen-bearing cells in vivo which could not be un-
covered by in vitro studies. As another indicator of in vivo
alloresponses, we examined the capacity of host CD47 / 
recipients to reject allogeneic donor BM grafts, a process
which is predominantly T cell dependent. Sublethally irra-
diated (5.5 Gray TBI) B6-CD47 /  or CD47 /  recipients
were given Balb/c T cell–depleted BM grafts. Donor chi-
merism levels at 6 wk after BMT revealed no significant
differences (P   0.29) between CD47 /  versus CD47 / 
recipients (39   8% vs. 27   7%) (n   18–20 per group).
Therefore, CD47 /  host T cells do not have a major de-
fect in allogeneic BM graft rejection.
Because MLR results were similar with CD47 /  versus
CD47 /  T cells, we sought to determine whether the im-
paired GVHD response was a result of poor T cell expan-
sion in vivo. NK-depleted Balb/c SCID mice were given
B6-CD47 /  or CD47 /  T cells (106 cells per recipient).
On day 6, we observed a mean of  2.6    106 donor
CD47 /  T cells as compared with  0.05   106 donor
CD47 /  T cells in recipient spleens (n   three per group
individually analyzed; P   0.001). We found  0.05   106
CD47 /  T cells in the thoracic duct lymphatics of a sepa-
rate cohort of mice that received CD47 /  T cells versus
0.6   106 T cells in mice given CD47 /  T cells (n   6
per group individually analyzed; P    0.001). Thus,
CD47 /  T cells do not appear to expand efficiently in or
are eliminated by CD47 /  allogeneic recipients.
CD47 /  BM Cannot Reconstitute Lethally Irradiated
CD47 /  Allogeneic or Congenic Recipients. The data sug-
gested that the reduction in GVHD by CD47 /  cells in
CD47 /  allogeneic recipients may not be due to a pro-
found defect in generating an alloresponse. The reduced
GVH response in irradiated recipients could be due to the
clearance of CD47 /  T cells by CD47 /  recipients. To
determine whether CD47 /  BM cells would be elimi-
nated by CD47 /  recipients, irradiated (6.5 Gray TBI) B6
recipients were given Balb/c T cell–depleted BM grafts
from CD47 /  or CD47 /  donors. CD47 /  BM infu-
sion resulted in 87% survival and a mean of 79% donor cells
in the peripheral blood at 2 mo after BMT. In marked con-
trast, recipients of CD47 /  BM cells died between days
12–19 after BMT (Fig. 2 a). Consistent with the presumed
hematopoietic failure, recipients of CD47 /  BM cells ex-
perienced a progressive severe (28%) body weight loss. To
determine whether the absence of CD47 expression was
responsible for impaired hematopoietic reconstitution in
the absence of an alloresponse, we infused congenic
CD47 /  BM into CD47 /  recipients. To preclude a T
cell or B cell immune response to the donor graft, we used
lethally irradiated (9.5 Gray TBI) CD47 / Rag1 /  or
Rag1 /  mice as recipients of either CD47 /  or CD47 / 
BM. CD47 /  BM was able to rescue CD47 /  recipients
from hematopoietic failure (Fig. 2 b). In contrast, CD47 / 
BM was not able to rescue lethally irradiated CD47 / 
Rag1 /  recipients. Day 14 Hct values indicated that the
Rag1 /  mice given CD47 /  but not CD47 /  BM were
dying of hematopoietic failure (13   2% vs. 41   1%; P  
0.001). Because congenic CD47 /  BM is able to rescue
CD47 /  but not CD47 /  recipients, these data are most
consistent with a non-T cell, non-B cell immune–medi-
ated resistance of CD47 /  recipients to CD47 /  BM.
Further evidence as to whether CD47 /  BM cells
would be preferentially eliminated in CD47 /  recipients,
lethally irradiated (9.0 Gray TBI) B6-Thy1.1 were given
equal numbers of B6-CD47 /  (CD45.2 , Thy1.2 ) and
congenic B6-CD45.1 CD47 / (Thy1.2 ) BM cells. Long-
term peripheral blood chimerism indicated that only B6-
CD45.1 CD47 /  cells repopulated the recipient (n   8
per group). Recipient splenectomy did not alter long-term
chimerism results, indicating that the spleen was not essen-544 Role of CD47 and Lymphohematopoietic Cell Clearance
Figure 1. CD47 /  T cells have a reduced GVHD lethality ca-
pacity. (a) Nonirradiated, NK cell–depleted Balb/c SCID recipi-
ents (n   5 per group) were given B6-CD47 /  or CD47 /  T
cells. Cell doses   10 6 are indicated in parentheses. Recipients
of 2   106 CD47 /  T cells had a significantly (P   0.0015)
higher survival rate versus those given 0.5   106 CD47 /  T
cells. (b) Irradiated (6.0 Gray TBI) bm1 recipients (n   8 per
group) were given B6-CD47 /  or B6-CD47 /  CD8  T cells.
Recipients of CD47 /  T cells had a significantly higher survival
versus B6-CD47 /  T cells. (c) Irradiated (6.0 Gray TBI) bm12
recipients (n    8 or 16 per group) were given B6-CD47 / 
CD4  T cells. Recipients of B6-CD47 /  CD4  T cells at a dose
of 0.3   106 had a significantly higher survival rate than recipients
of 10-fold fewer B6-CD47 /  cells.545 Blazar et al. Brief Definitive Report
tial for the clearance of CD47 /  BM cells. Together, these
data indicate that CD47 /  BM cells are preferentially elim-
inated by CD47 /  recipients.
Because long-term reconstitution could not be achieved
with CD47 /  BM, we used a short-term in vivo assay to
assess the proliferation of CD47 /  BM cells in CD47 / 
recipients early after infusion. We considered the possibility
that NK cells were involved in graft resistance as has been
shown for congenic MHC class I /  BM cells. When
CD47 /  BM is given to lethally irradiated (9.5 Gray TBI)
CD47 /  recipients, we observed high proliferation by day
5 after BMT (Table I). In marked contrast, CD47 /  BM
was unable to proliferate in CD47 /  recipients regardless
as to whether host NK cells were depleted. These data in-
dicate that CD47 /  BM is able to home to the spleen and
proliferate in CD47 /  but not in CD47 /  recipients
early after BMT.
Host Macrophages Can Resist the Engraftment of CD47 / 
Donor Cells Transferred into Allogeneic CD47 /  Recipients.
To determine whether host CD47 /  macrophages would
clear CD47 /  donor T cells, NK-depleted Balb/c SCID
recipients were given B6-CD47 /  or B6-CD47 /  spleen
cells and analyzed 6 d after transfer (Table II). In marked
contrast to the fivefold expansion of CD47 /  T cells,
CD47 /  T cells failed to reconstitute the spleen of alloge-
neic SCID recipients. Host macrophage and partial DC de-
pletion by clodronate reduced the expansion of allogeneic
T cells in controls, suggesting that host APCs supported the
expansion of CD47 /  T cells in CD47 /  recipients. In
contrast, APC depletion increased the absolute number of
donor CD4  and CD8  T cells in the spleen of SCID re-
cipients of CD47 /  T cells, consistent with a partial resto-
ration of donor CD47 /  T cell engraftment.
Next, we sought to determine whether macrophage-
poor organs had a higher number of donor CD47 /  T
cells as compared with macrophage-rich organs. As com-
pared with nonconditioned or sublethal irradiated recipi-
ents, lethally irradiated recipients may have an impairment
in the removal of donor CD47 /  T cells by CD47 / 
host cells. Therefore, we chose a lethal irradiation system
in which B10.BR recipients were prepared with lethal ir-
radiation (8.0 Gray TBI) to increase the likelihood of do-
Figure 2. CD47 /  but not CD47 /  BM rescues
lethally irradiated recipients. (a) B6 recipients were
given 6.5 Gray TBI and infused with Balb/c-
CD47 /  or CD47 /  BM (n   15 per group). Re-
cipients of CD47 /  BM had a significantly lower
survival versus those given CD47 /  BM. (b) Le-
thally irradiated (9.5 Gray TBI) B6-CD47 /  or B6-
CD47 /  Rag1 /  recipients (n    15 per group)
were infused with B6-CD47 /  BM. B6-CD47 / 
recipients of B6-CD47 /  BM had a significantly
higher survival than B6-CD47 / Rag1 /  recipients
given B6-CD47 /  BM.546 Role of CD47 and Lymphohematopoietic Cell Clearance
nor T cell infiltration into GVHD target organs. Cohorts
of mice were reconstituted with BM and either B6
CD47 /  or CD47 /  T cells. Recipients of allogeneic
CD47 /  T cells uniformly succumbed to GVHD lethal-
ity, albeit significantly delayed as compared with recipients
receiving CD47 /  T cells (data not shown). Immunohis-
tochemistry was performed on tissue sections obtained
from known GVHD target organs (liver, colon, and skin)
in this model system. On day 14 after BMT, there were at
least 15-fold fewer donor T cells present in the liver of re-
cipients of CD47 /  versus CD47 /  T cells (mean values:
CD4  T cells, 9   7 vs. 133   11/mm2; CD8  T cells: 7  
2 vs. 122   32/mm2, respectively). The liver is a rich
source of Kupffer cells, macrophages which clear cellular
and particulate material. In lethally irradiated recipients of
MHC disparate donor T cells, 25% of Kupffer cells are of
host origin as late as 2 wk after BMT (18). Thus, the liver
could function in part as a clearinghouse for CD47 /  T
cells. In the skin, also a rich source of APCs, T cells were
present at fivefold lower frequency in recipients of CD47 / 
as compared with CD47 /  T cells (mean values: CD4 
T cells, 19   6 vs. 11   1/mm2; CD8  T cells: 36   18
vs. 0   0/mm2, respectively). In contrast, in other organs
not as rich in macrophages, such as the colon, donor T cell
infiltration in recipients of CD47 /  T cells was reduced
by only 63% as compared with recipients of CD47 /  T
cells (mean values: CD4  T cells, 91   41 vs. 322   89/
mm2; CD8  T cells: 150   17 vs. 350   35/mm2, respec-
tively). These data are consistent with a greater degree of
clearance of allogeneic CD47 /  T cells in macrophage-
rich as compared with macrophage-poor organs in
CD47 /  recipients.
Table I. CD47 /  BM Cells Will Proliferate in CD47 /  but not CD47 /  Recipientsa
Experiment No. No. Analyzed Donor Recipient NK depletion Mean   SEM
16  /   /  no 142,645   24,908
16  /   /  no 484   114
16  /   /  yes 4,225   9,347
25  /   /  no 125,453   22,089
25  /   /  no 331   47
25  /   /  yes 407   99
34  /   /  no 146,057   17,621
35  /   /  no 532   248
35  /   /  yes 518   95
aB6-CD47+/+ (termed +/+) or B6-CD47 /  (termed  / ) recipients were lethally irradiated (9.5 Gy TBI), and given B6-CD47 /  BM cells. Co-
horts of recipients, as indicated, were depleted of NK cells prior to BM infusion. On day 5, [125I]deoxyuridine and fluorodeoxyuridine were given.
Day 6 spleens were harvested and incorporated radioactivity was determined. Values are mean  1 SEM. No., number.
Table II. CD47 /  T Cells Have Impaired In Vivo Engraftment As Compared to CD47+/+ T Cells when Infused into Nonconditioned
Allogeneic Recipientsa
Group DMDP Spleen No. CD4  Total CD4  CD8  Total CD8 
%%
 / →Balb/c SCID no 25   5 10   1 2.4   0.5 20   5 5.0   1.6
 / →Balb/c SCID yes 3   2a 13   4  0.5   0.4a 34   7a 1.0   0.4a
 / →Balb/c SCID no 6   2c 0   0c 0.0   0.0c 0   0c 0.0   0.0c
 / →Balb/c SCID yes 2   1a 10   3a 0.2   0.2b 28   18a 0.4   0.3a, c
Nonconditioned, NK cell–depleted Balb/c SCID were given T cells (106 cells per recipient) from B6-CD47+/+ or B6-CD47 / donors as indicated.
Mice received either saline or liposomal DMDP injections on days 2 and 1. Four mice per group were individually studied on day 6 after transfer for
evidence of engraftment of donor T cells in the spleen of recipients. Data for lymphoid cell subsets are shown. All cell numbers are  10 6. DMDP,
dichloromethylene diphosphanate (clodronate). No., number.
aP   0.05 versus no DMDP group.
b0.1   P   0.05 versus no DMDP group.
cP   0.05 versus CD47+/+ donor T cells.547 Blazar et al. Brief Definitive Report
Host CD47 /  Splenic DCs and Macrophages Rapidly En-
gulf Donor CD47 /  Lymphohematopoietic Cells In Vivo. In
contrast to the critical role of host macrophages in RBC
clearance (8, 11), these cells appeared to play only a partial
role in lymphohematopoietic cell clearance. To directly ex-
amine which host cell populations would engulf CD47 / 
lymphohematopoietic cells, B6-CD47 /  recipients were
given CFSE-labeled LN cells from B6-CD47 /  or
CD47 /  donors. Splenocytes were analyzed at various
time periods after infusion to enumerate CD47 /  versus
CD47 /  cells and determine whether there was evidence
that CD47 /  T cells were phagocytosed to a greater ex-
tent than CD47 /  T cells. Flow cytometric analysis indi-
cated that a higher proportion of splenic CD11b CD11c 
DCs had phagocytosed CFSE-labeled CD47 /  than
CD47 /  congenic T cells by 1 h after infusion (5.5 vs.
1.0%, respectively; Fig. 3 a). Analysis of time kinetics re-
vealed that CFSE-labeled CD47 /  versus CD47 /  T
cells had been engulfed by a higher proportion of
CD11b CD11c  DCs (1, 2, and 4 h after infusion),
CD11b CD11c  DCs (1 h), and F4/80 CD11c  mac-
rophage populations (1 h; Fig. 3 b). Splenic sections ob-
tained 1 h after infusion showed that CFSE-labeled T cells
of both genotypes migrated to the periarteriolar sheath ar-
eas but approximately one-half of CFSE-labeled CD47 / 
and virtually no CD47 /  T cells could be found inside
host CD11c  DCs (Fig. 3 c). By 1 d after infusion, there
were no detectable CFSE-labeled CD47 /  T cells present
in the spleen as determined by either flow cytometry or
splenic sections, in contrast to readily detectable CFSE-
labeled CD47 /  T cells which were still present (data not
shown). Thus, CD11b  DCs and to a lesser extent
CD11b  DCs and macrophages preferentially engulfed
CD47 /  versus CD47 /  T cells.
Discussion
Our data show that CD47 expression is necessary to pre-
vent host CD47 /  splenic DCs and macrophages from
clearing CD47 /  lymphohematopoietic cells. In the ab-
sence of CD47 expression, donor BM reconstituting cells
are rapidly cleared in CD47 /  recipients indicating that
this antigen is expressed on short-term reconstituting BM
cells. Congenic or allogeneic donor T cells which do not
express CD47 are rapidly cleared by CD47 /  DCs and
macrophages. Thus, CD47 antigen on BM cells and T cells
Figure 3. CD47 /  lymph node cells are cleared by
APC in vivo. LN cells were isolated from B6-CD47 / 
or CD47 /  mice, CFSE-labeled, and injected (5  
106 per mouse) intravenously into B6 recipients. Some
mice were left uninjected (time 0 h). Spleens from mice
were harvested 1, 2, and 4 h after injection (n   3 per
time point) and stained with mAb (anti-B220, anti-
CD3, anti-CD11c, anti-CD11b, or anti-F4/80) to
identify CD11b   DCs (B220 , CD3 , CD11c ),
CD11b  DCs (B220 , CD3 , CD11c ), and F4/80 
macrophages (B220 , CD3 , CD11c ). A portion of
the spleens examined using confocal microscopic analy-
sis. (a) Representative histograms depicting CD11b 
DCs 1 h after injection of CD47 /  cells (center),
CD47 /  cells (bottom) or not injected (top) are
shown. (b) Kinetics of the appearance of
CFSE CD11b DCs (squares) CD11b  DCs (circles),
and F4/80  macrophages (triangles) after injection of
CD47 /  (open symbols) or CD47 /  (closed symbols)
LN cells. The percentage of CFSE  cells contained
within the indicated cell population is listed on the y
axis. Values for standard error of the mean were all
 26% except for CD11b  DCs engulfing CD47 /  T
cells. At the indicated time points, there was a signifi-
cantly (P    0.03) higher proportion of CD11b 
CD11c  (1, 2, 4 h) DCs, CD11b  DCs (1 h), and F4/
80  macrophages (1 h) which had engulfed CFSE-
labeled CD47 /  versus CD47 /  cells. (c) Photomi-
crographs of spleen sections from mice at 1 h after injec-
tion with CFSE-labeled CD47 /  (left) or CD47 / 
(right) LN cells (green). CD11c  DCs are red.548 Role of CD47 and Lymphohematopoietic Cell Clearance
can function as a negative regulator of the scavenger effects
of host DCs and macrophages in eliminating lymphohe-
matopoietic cells which fail to express this antigen.
CD47 /  BM is able to proliferate and reconstitute le-
thally irradiated CD47 /  but not CD47 /  recipients.
These data are consistent with a clearing of CD47 /  he-
matopoietic progenitor cells by the host as further evi-
denced by an almost complete absence of BM proliferation
early after transfer. Similarly, despite the pressure to gener-
ate effective alloresponses and for homeostatic expansion in
vivo, B6-CD47 /  T cells could not be detected in alloge-
neic Balb/c SCID CD47 /  recipients. Recently, we have
reported that CD47 /  RBCs are cleared in CD47 / 
mice by splenic macrophages (8, 11). The macrophage re-
ceptor engaged by CD47 is SIRP , a signal-regulatory
protein which inhibits tyrosine-kinase signaling pathways
(8, 11, 19). NK inhibitory receptors also recruit and acti-
vate the same tyrosine-kinase signaling pathways so that
NK cells won’t eliminate lymphohematopoietic cells that
express self-MHC class I antigens (20, 21). Conversely, tu-
mor cells that have lost or downregulated MHC class I an-
tigens could be removed by NK cells (19). In an analogous
fashion, splenic macrophages clear RBCs which lack MHC
antigens. Although an ovarian cancer cell line has been
shown to be CD47 deficient, it is possible that CD47 ex-
pression is downregulated on other types of tumors or
damaged lymphohematopoietic cells (22). In those in-
stances, a low level of CD47 expression may cause the host
to eliminate these cells.
Regulation of CD47 expression may be an important
mechanism for host macrophages to remove damaged
RBCs since the clearance of opsonized RBCs is controlled
by CD47-SIRP . For other lymphohematopoietic cells
such as T cells and BM cells, DCs appear to be more criti-
cal than macrophages in eliminating CD47 /  cells in a
CD47 /  microenvironment. We provide direct evidence
that both CFSE-labeled CD47 /  and CD47 /  T cells
initially localized to the splenic periarteriolar sheath but
that CD47 /  T cells were engulfed by CD11b  DCs and
to a lesser extent by CD11b  DCs and macrophages by 1 h
after infusion, resulting in complete clearance of CD47 / 
but not CD47 /  T cells within 1 d after infusion. In
contrast, RBCs normally stay within the macrophage-rich
red pulp area of the spleen, which is why macrophages are
the primary populations to eliminate CD47 /  RBCs.
Consistent with CFSE-labeled T cell data, the elimination
of host splenic CD11b CD11c  DCs and macrophages by
clodronate only partially inhibited CD47 /  T cell clear-
ance by CD47 /  recipients. Because DCs are widely dis-
tributed throughout the body especially including DC-
rich tissues such as the liver, lung, LN, and skin as well as
the spleen, we hypothesize that the spleen may not be the
major site of clearance for CD47 /  T cells or BM. In sup-
port of this hypothesis, irradiated, splenectomized recipi-
ents given equal numbers of congenic CD47 /  and
CD47 /  BM cells had exclusively congenic CD47 / 
BM-derived cells present in the peripheral blood when an-
alyzed 1 mo later. Thus, CD47 /  DCs and macrophages
engulf and clear CD47 /  lymphohematopoietic cells, a
process which can occur both within or outside the spleen.
For lymphohematopoietic cells which express MHC anti-
gens, CD47 expression may represent a safeguard for elim-
inating abnormal cells that have not downregulated MHC
class I antigens.
We were unable to demonstrate a critical role for CD47
in regulating alloresponses. In vitro, MLR responses with
CD47 /  T cells were similar to CD47 /  T cells. In vivo,
CD47 /  recipients could reject allogeneic donor BM
grafts indicating that host antidonor responses by CD47 / 
T cells were not markedly impaired. Several investigators
have shown that CD47 can costimulate T cells that have
received TCR signals (3–7, 19). In nonirradiated or suble-
thally irradiated recipients, the donor T cells are rapidly
cleared and therefore not available to mediate lethality. Be-
cause under lethal irradiation conditions, recipients of allo-
geneic CD47 /  T cells eventually succumbed to GVHD
lethality, it is possible that heavy irradiation either elimi-
nated SIRP -expressing host cells or inhibited their func-
tion. Regardless, CD47 /  T cells can cause lethality, pro-
viding evidence that CD47 /  T cell alloresponses are not
markedly impaired in vivo.
In summary, we have found that CD47 expression is re-
quired to prevent clearance of lymphohematopoietic cells
by DCs and macrophages. This rapid response mechanism
may protect the host from damaged or defective cells that
downregulate CD47 antigen in disease states. Approaches
to reduce CD47 antigen expression on lymphohematopoi-
etic cells may provide a means of eliminating abnormal or
harmful cells in various disease settings.
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